Resources
9 Results (showing 1 - 9)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/19/2021 (updated 4/5/2024)
The present article reviews whether available efficacy and safety data support the pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD) in patients with concurrent substance use disorders (SUD). Arguments for and against treating adult ADHD with active SUD are discussed
Posted 3/5/2021 (updated 4/5/2024)
The United States is facing a crisis of opioid-related overdose. At this time, more people die of overdose every year than died of AIDS at the peak of the HIV epidemic. Communities seek effective responses to prevent opioid death.
Posted 3/3/2021 (updated 4/5/2024)
The National Governors Association and the American Correctional Association recently released a new toolkit on "Expanding Access to Medications for Opioid Use Disorder in Corrections and Community Settings: A Roadmap for States to Reduce Opioid Use Disorder for People in the Justice System."
This roadmap highlights existing state efforts and serves as a policy development tool for Governors and state officials seeking to improve coordination and bolster existing efforts across state agencies to address OUD among people involved in the justice system by expanding access to evidence-based medications. The following are key steps for supporting MOUD in corrections settings.
Posted 12/29/2020 (updated 4/4/2024)
Whereas outpatient treatment with medication for opioid use disorder (MOUD) is evidence based, there is a large network of inpatient facilities in the US that are reimbursed by commercial insurers and do not typically offer MOUD. This study is a comparison of rates of overdose and hospitalization after initiation of medication for Opioid Use Disorder in the inpatient vs outpatient setting.
Posted 9/22/2021 (updated 4/3/2024)
PCSS's PCSS-Implementation (PCSS-I) initiative is here to support clinicians and their clinical programs by implementing medications for opioid use disorder (MOUD) into your practice.
PCSS-I has clinical and implementation experts as PCSS-I Facilitators available to work with you and your team to develop strategies tailored specifically to support your needs. There is no cost to participate.
Posted 7/19/2021 (updated 4/2/2024)
Drug overdose deaths in the United States hit a record high in 2017, with an estimated 72,000 deaths. Over two-thirds of those deaths, roughly 47,600, were due to opioids.These staggering numbers continued in 2018, as over 67,000 drug overdose deaths occurred, and opioids were involved in rough 46,800 of those overdose deaths.
This roadmap highlights existing state efforts and serves as a policy development tool for Governors and state officials seeking to improve coordination and bolster existing efforts across state agencies to address OUD among people involved in the justice system by expanding access to evidence-based medications.
Posted 6/17/2021 (updated 4/2/2024)
Fueled by misinformation, fentanyl panic has harmed public health through complicating overdose rescue while rationalizing hyper-punitive criminal laws, wasteful expenditures, and proposals to curtail vital access to pain pharmacotherapy. To assess misinformation about health risk from casual contact with fentanyl, we characterize its diffusion and excess visibility in mainstream and social media.
Posted 9/1/2020 (updated 3/29/2024)
This toolkit is intended to give prescribers a broad overview of medication utilization management techniques and describe ways that prescribers can facilitate patient access to needed medications. It focuses on prescribed medications that are filled by retail pharmacies; it does not cover the processes for methadone or specialty pharmacy products, such as injectable or implantable medications, all of which are commonly covered by a patient’s medical benefit rather than their pharmacy benefit.
Posted 3/9/2022 (updated 3/27/2024)
IMPORTANCE Thousands of pregnant people with opioid use disorder (OUD) enter US jails annually,
yet their access to medications for OUD (MOUD) that meet the standard of care (methadone and/or
buprenorphine) is unknown.
OBJECTIVE To assess the availability of MOUD for the treatment of pregnant individuals with OUD
in US jails.